← Back to Search

Intensive Leg Exercise for Spastic Diplegia

N/A
Recruiting
Led By Jaynie Yang, Phd
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Periventricular white matter injury from encephalopathy of prematurity
Be younger than 18 years old
Must not have
Botulinum toxin-A (BTX-A) injections in the legs in the last 6 months
Substantial upper extremity involvement - Manual Abilities Classification System (MACS) Level ≥3
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to 6 months
Awards & highlights

Summary

This trial compares two methods of physical therapy for improving leg movement in young children with a type of muscular paralysis.

Who is the study for?
This trial is for young children with spastic diplegia, a form of cerebral palsy affecting the legs. Participants must have bilateral motor impairment and be able to stand with support but not have severe upper limb involvement, recent leg injections (BTX-A), uncontrolled epilepsy, or conditions that make intensive exercise unsafe.Check my eligibility
What is being tested?
The study tests whether 3 months of early intensive leg exercises can improve walking better than standard physiotherapy in children with spastic diplegia resulting from periventricular leukomalacia.See study design
What are the potential side effects?
While specific side effects are not listed, intensive exercise may lead to muscle soreness, fatigue, and potential strain on muscles and joints in these young participants.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have brain damage from premature birth complications.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received BTX-A injections in my legs within the last 6 months.
Select...
I have significant difficulty using my hands and arms for daily tasks.
Select...
I have not had uncontrolled seizures or infantile spasms in the last 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Gross Motor Functional Measure - 66 Items (GMFM-66)
Secondary outcome measures
Change in stiffness at the ankle
Change on Pediatric Quality of Life Measure module for cerebral palsy (PedsQL CP)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Immediate training groupExperimental Treatment1 Intervention
Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
Group II: Delay training groupActive Control1 Intervention
Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intensive exercise
2011
Completed Phase 4
~450

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
901 Previous Clinical Trials
387,490 Total Patients Enrolled
1 Trials studying Spastic Diplegia
4 Patients Enrolled for Spastic Diplegia
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,354 Previous Clinical Trials
26,460,459 Total Patients Enrolled
Jaynie Yang, PhdPrincipal InvestigatorUniverstiy of Alberta

Media Library

Intensive exercise Clinical Trial Eligibility Overview. Trial Name: NCT03672877 — N/A
Spastic Diplegia Research Study Groups: Immediate training group, Delay training group
Spastic Diplegia Clinical Trial 2023: Intensive exercise Highlights & Side Effects. Trial Name: NCT03672877 — N/A
Intensive exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT03672877 — N/A
~4 spots leftby Dec 2024